Phase I/II Study Of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced MDS, CML, AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant
Latest Information Update: 07 Apr 2022
At a glance
- Drugs INNO 305 (Primary) ; Aldesleukin; Antineoplastics
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders; Polycythaemia vera; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 May 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 07 Jun 2012 Additional lead trial centre( Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium) and investigator( Merav Bar) identified as reported by ClinicalTrials.gov.